Endolastic develops minimally invasive endoscopic solutions using its proprietary Endolastic™ technology to treat Gastroesophageal Reflux Disease (GERD), obesity, and Type 2 Diabetes. The company’s procedures, such as the Anti-Reflux Band Mucosectomy and Endoscopic Band Gastroplasty, provide effective symptom relief and sustainable weight loss through outpatient treatments with minimal recovery time.
Funding
Funding not disclosed
Founders
Product
Problem
Gastroesophageal Reflux Disease (GERD), obesity, and Type 2 Diabetes often require invasive surgical interventions or long-term medication, presenting challenges in terms of patient recovery, potential complications, and ongoing management. Current endoscopic treatments may not offer a complete or lasting solution, leading to persistent symptoms and the need for repeated procedures.
Solution
Endolastic is developing a minimally invasive, ligation-based endoscopic platform that utilizes its proprietary Endolastic™ technology to address the root causes of GERD, obesity, and Type 2 Diabetes. The platform delivers precise tissue management through ligation, enabling targeted treatment of dysfunctional GI tissue. Procedures such as Anti-Reflux Band Mucosectomy (ARBM) for GERD and Endoscopic Band Gastroplasty (EBG) for obesity aim to provide long-term relief and sustainable outcomes without the need for extensive surgery or ongoing medication. The platform's design allows for quick outpatient procedures with minimal recovery time, promoting patient comfort and access.
Target Audience
The primary target audience includes endoscopists and gastroenterologists seeking minimally invasive and effective solutions for treating GERD, obesity, and Type 2 Diabetes, as well as hospitals and ambulatory surgery centers (ASCs) looking to expand their metabolic disease treatment offerings.
Features
- Minimally invasive ligation-based procedures performed endoscopically, eliminating the need for incisions.
- WindowLock™ bands applied to create pressure zones that stimulate natural tissue regeneration.
- Procedures typically completed in under 30 minutes, reducing procedure time and improving patient throughput.
- Conscious sedation (MAC Sedation) reduces the need for general anesthesia, enhancing patient comfort and enabling ASC patient access.
- Repeatable and adjustable procedures allow for customized treatment and potential retreatment if necessary.
- Targets dysfunctional GI tissue to address the source of the condition, rather than just managing symptoms.
- Designed for outpatient settings, facilitating convenient access and reducing healthcare costs.